Abiprubart (KPL-404) demonstrated improvements in disease activity in patients with refractory rheumatoid arthritis (RA), compared with placebo, according to new Phase 2 data presented at the 2024 European Congress of Rheumatology (EULAR).

These findings showed statistically significant reduction in the Disease Activity Score of 28 Joints using C-reactive Protein (DAS28-CRP) scores at Week 12, particularly in those treated weekly with 5mg/kg abiprubart, and a well-tolerated safety profile.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/abiprubart-reduces-disease-activity-refractory-rheumatoid-arthritis